Drug Profile
Research programme: JAK3 inhibitors - Pfizer
Alternative Names: PS 608504; WYA-152038/PS 513992Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pharmacopeia Drug Discovery
- Developer Ligand Pharmaceuticals; Pfizer
- Class
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Eye disorders; Inflammation; Psoriasis
Highest Development Phases
- Suspended Inflammation
- No development reported Immunological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 05 Apr 2011 Ligand's JAK3 inhibitors (topical) are available for licensing. www.ligand.com